Tides Medical

Executive Summary

Tides Medical, founded in 2012 and headquartered in Lafayette, Louisiana, is a private biologics company focused on developing and commercializing high-quality amniotic tissue grafts for wound care and surgical applications. The company operates an integrated model with an in-house tissue sourcing division, LOFT, enabling control over the supply chain from donated placental tissue to finished, room-temperature stable skin substitutes. Beyond manufacturing, Tides distinguishes itself by providing comprehensive reimbursement and billing support to healthcare providers, a critical service that facilitates patient access and reduces administrative burdens. This full-service approach positions Tides as a partner rather than just a supplier, building loyalty among clinicians and health systems. The wound care market represents a significant and growing opportunity, driven by an aging population and rising incidence of chronic wounds such as diabetic ulcers and pressure sores. Tides Medical’s amniotic tissue grafts offer a promising regenerative solution that can accelerate healing and reduce complications. With its vertically integrated business model and emphasis on provider support, the company is well-placed to capture market share. However, as a private company with limited public information, the scale of its commercial operations and financial performance remains unclear. Key upcoming catalysts include potential FDA clearances for new product lines, expansion of reimbursement codes, and strategic partnerships that could accelerate growth.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance for next-generation amniotic graft for chronic wounds60% success
• Q4 2026Expansion of Medicare coverage for amniotic tissue products70% success
• Q2 2026Strategic partnership with a national wound care distributor50% success